Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin
Cumulative Irritation
Primary: Number of Subjects That Showed no Significant Irritation — 0 participants
N/A N=68 Human Repeated Insult Patch Test
Dermatitis · Allergy · Contact Allergy
Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score
Phase 1 N=43 21 Day Cumulative Skin Irritation of RUT058-60
Irritation/Irritant
Primary: Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin — 1.00; 2.46; 1.34; 0.58 units on a scale
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
Dermal Irritation
Primary: Number of Subjects That Showed Erythema Based on 5 Point Scoring Scale — 0 Participants
Phase 1 N=46 A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
Healthy
Primary: Skin Irritation Score — 0; 0; 339; 15 Normalized cumulative irritation score — p=<0.0001
N/A N=86 HRIPT for Collagen Dressing
Skin Sensitisation
Primary: Skin Sensitization Reaction Using Berger and Bowman Scale — 0; 0; 0; 0 score on a scale
N/A N=118 Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
Allergic Sensitization
Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants
Phase 3 N=39 Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth
Surgery
Primary: Grading Scale for Visual Evaluation of Skin Condition — 0; 0; 0; 0 Scores Ranging (0-7)
Phase 4 N=26 A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
Acne Vulgaris
Primary: Expert Grader Assessment - Erythema — 0.0; 0.0; 0.4; 2.0 Scores on a Scale
Phase 4 N=26 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face
Acne Vulgaris
Primary: Comparative Assessment of Facial Irritation and Cutaneous Effects. — 1.1; 2.7; 3.2; 6.2 Scores on a Scale
N/A N=222 Human Repeat Insult Patch Test to Evaluate Personal Lubricants
Erythema · Edema
Primary: Number of Patients That Showed Sensitization Reaction to the Test Material at Challenge — 0 Participants
Phase 4 N=25 Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.
Acne Vulgaris
Primary: Assessment of Facial Irritation and Cutaneous Effects — 4.8; 3.9; 8.8; 6.7 Ordinal data treated as interval
Phase 4 N=162 Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face
Acne Vulgaris
Primary: Facial Irritation and Cutaneous Effects — 1.5; 5.4; 3.1; 7.8 Scores on a Scale
Phase 3 N=32 Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)
Hypersensitivity
Primary: Cumulative Irritation Total (CIT) Score — 0.0; 20.0; 0.0 Score on a scale
N/A N=280 To Evaluate Skin Irritation and Skin Sensitisation of Developmental Cosmetic Facial Products
Skin Care
Primary: Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 — 2; 1; 1; 0 Number of participants
N/A N=209 Repeated Insult Patch Test of Personal Lubricants
Erythema · Edema
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 0 participants
Phase 2 N=23 Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model
Perinatal Depression · Post Partum Depression · Depression, Postpartum
Primary: Mean Threat Processing Bias During Visual Dot-probe Paradigm Over Time — -0.57; 36.92; -9.04; -42.35 attention bias in milliseconds — p=0.160
N/A N=240 To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Participants
Skin Care
Primary: Combined Skin Irritation (Dermal Response) and Superficial Irritation (Other Effects) Scores at Induction Phase at Day 3 — 0; 0 Score on scale
N/A N=58 Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
Erythema · Sensitisation
Primary: Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix — 53; 49; 0; 4 Participants
N/A N=40 To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test
Skin Care
Primary: Frequency of Dermal Response Score at 15-30 Minutes Post Patch Removal — 0; 0; 0; 0 Participants
Phase 4 N=128 Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Skin Irritation
Primary: Area of Erythema and Elevated Responses of Skin to Product — 91; 68; 33; 42 participants
N/A N=97 Hostile Interpretation Bias Training to Treat Irritability
Irritable Mood · Mood Disorders
Primary: Change in Interpretation Bias — 1.53; 0.55 units on a scale — p=<0.001
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 2 N=22 Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis
Nonallergic Irritant Rhinitis
Primary: Change in Total Symptom Score — -5; 2 score on a scale
Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
N/A N=80 Oral Irritation Study of Two Experimental Mouthrinses
Oral Manifestations
Primary: Percentage of Participants With an Abnormal Condition by Anatomical Site at Screening — 0; 0; 0; 0 Percentage of Participants